Fariborz Kamal, Ph.D.

Fariborz Kamal, Ph.D.

Former Chief Operating Officer & Presidentat4D Molecular Therapeutics· In proxies 2022–2025

Pay in FY2025+96% from the year before · 4D Molecular Therapeutics stock +34.6% the same year

Fariborz Kamal, Ph.D. was paid $1.4M in FY2025 (Dec), up 96%. 4D Molecular Therapeutics stock rose 34.6% that year.

Pay$100 in the stock at the end of FY21 → $34
Pay is from the Summary Compensation Table of each 4D Molecular Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. 4D Molecular TherapeuticsPublic company · 4 yr
    • Former Chief Operating Officer & President2022 – Present · 4 yrStock in role -41%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?